Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity.

Authors: Miners, James Scott  Baig, Shabnam  Tayler, Hannah  Kehoe, Patrick Gavin  Love, Seth 
Citation: Miners JS, etal., J Neuropathol Exp Neurol. 2009 Aug;68(8):902-14. doi: 10.1097/NEN.0b013e3181afe475.
Pubmed: (View Article at PubMed) PMID:19606063
DOI: Full-text: DOI:10.1097/NEN.0b013e3181afe475

Experimental reduction of neprilysin (NEP) or insulin-degrading enzyme (IDE) in vivo exacerbates beta-amyloid accumulation in the brain. The level of these enzymes is reportedly reduced during aging and in postmortem brains of patients with sporadic Alzheimer disease (AD). To distinguish between primary decreases in NEP and IDE activity that might contribute to beta-amyloid accumulation and decreases secondary to neurodegenerative changes in AD, we measured NEP and IDE levels by indirect sandwich ELISA and enzyme activities by immunocapture-based fluorogenic assays in postmortem frontal cortex from patients of different ages and at different pathological stages of AD, as indicated by Braak tangle stage. The ELISA measurements of neuron-specific enolase were used to adjust for neuronal loss. Both unadjusted and neuron-specific enolase-adjusted NEP levels and activity were significantly increased in AD and positively correlated with Braak stage but negatively with age in AD patients. Insulin-degrading enzyme activity was higher in AD than controls; this was significant after adjustment for neuron-specific enolase level; unadjusted IDE protein level was decreased in AD but not after adjustment. Our findings suggest that reduction in NEP and IDE activity is not the primary cause of beta-amyloid accumulation in AD, but rather a late-stage phenomenon secondary to neurodegeneration.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 13801019
Created: 2018-10-26
Species: All species
Last Modified: 2018-10-26
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.